Firebrick Pharma Ltd
Firebrick Pharma Raises $1.5m to Advance Product Development and Commercial Expansion
Firebrick raises $1.5m via 31.9m shares at $0.047, 16.5% discount to VWAP with 1-for-2 options; Indonesia grants Nasodine approval, unlocking SE Asia growth.
Market wrap: share market trends lower as Middle East war threatens to expand
The probability that Israel has launched an attack on Iran was enough to send share market traders scurrying for cover, with oil and gold two of the very few safe harbours amidst severe global share market caution. Confirmation from US government officials that Israel had launched a retaliatory attack on Iran in reply to some […]
Firebrick Pharma launches antiseptic nasal spray into US online market
An antiseptic nasal spray developed by Melbourne-based Firebrick Pharma (ASX: FRE) to attack the common cold has been officially launched online for US customers. Nasodine is now available to purchase from the company’s website and online promotion is commencing across the nation this week. The povidone-iodine (PVP-I) product has been designed to maintain nasal hygiene […]